PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Nov 21
Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedNov 21, 2024
DataAggregated Company Financials
Companies33
- 7D-5.5%
- 3M-1.8%
- 1Y15.4%
- YTD11.1%
Over the last 7 days, the Biotech industry has dropped 5.5%, driven by PeptiDream declining 12%. In contrast, CellSeed has gained 19%. This takes the industry's 12 month performance to a gain of 15%. Earnings are forecast to grow by 9.7% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 21 Nov 2024 | JP¥1.0t | JP¥207.5b | -JP¥10,836,549,000.00 | 19.4x | -94.7x | 4.9x |
| Sat, 19 Oct 2024 | JP¥1.1t | JP¥214.3b | -JP¥3,941,502,000.00 | 21.8x | -285.1x | 5.2x |
| Mon, 16 Sep 2024 | JP¥1.0t | JP¥210.1b | -JP¥469,229,000.00 | 18.5x | -2218.2x | 5x |
| Wed, 14 Aug 2024 | JP¥971.5b | JP¥213.8b | JP¥1.9b | 13.4x | 519.7x | 4.5x |
| Fri, 12 Jul 2024 | JP¥1.1t | JP¥187.7b | -JP¥15,773,047,000.00 | 93.7x | -67.5x | 5.7x |
| Sun, 09 Jun 2024 | JP¥828.3b | JP¥195.7b | -JP¥14,113,284,000.00 | 96.5x | -58.7x | 4.2x |
| Tue, 07 May 2024 | JP¥802.6b | JP¥199.1b | -JP¥14,617,545,000.00 | 77.4x | -54.9x | 4x |
| Thu, 04 Apr 2024 | JP¥745.3b | JP¥194.2b | -JP¥15,456,803,000.00 | 61.3x | -48.2x | 3.8x |
| Sat, 02 Mar 2024 | JP¥814.8b | JP¥196.2b | -JP¥19,179,997,000.00 | 65.5x | -42.5x | 4.2x |
| Mon, 29 Jan 2024 | JP¥779.2b | JP¥222.3b | -JP¥12,604,827,000.00 | 17.6x | -61.8x | 3.5x |
| Wed, 27 Dec 2023 | JP¥773.1b | JP¥224.2b | -JP¥12,970,409,000.00 | 16.3x | -59.6x | 3.4x |
| Fri, 24 Nov 2023 | JP¥787.4b | JP¥221.9b | -JP¥12,426,487,000.00 | 17.2x | -63.4x | 3.5x |
| Sun, 22 Oct 2023 | JP¥741.7b | JP¥223.0b | -JP¥14,478,735,000.00 | 20.5x | -51.2x | 3.3x |
| Tue, 19 Sep 2023 | JP¥875.3b | JP¥223.0b | -JP¥14,518,735,000.00 | 27.6x | -60.3x | 3.9x |
| Thu, 17 Aug 2023 | JP¥860.0b | JP¥225.1b | -JP¥16,853,776,000.00 | 49.5x | -51x | 3.8x |
| Sat, 15 Jul 2023 | JP¥927.2b | JP¥223.0b | -JP¥19,224,669,000.00 | 53.5x | -48.2x | 4.2x |
| Mon, 12 Jun 2023 | JP¥967.6b | JP¥220.6b | -JP¥21,578,670,000.00 | 46.3x | -44.8x | 4.4x |
| Wed, 10 May 2023 | JP¥925.0b | JP¥218.2b | -JP¥20,061,938,000.00 | 21.3x | -46.1x | 4.2x |
| Fri, 07 Apr 2023 | JP¥911.9b | JP¥218.3b | -JP¥21,583,164,000.00 | 21.5x | -42.3x | 4.2x |
| Sun, 05 Mar 2023 | JP¥923.3b | JP¥216.2b | -JP¥18,991,580,000.00 | 20.7x | -48.6x | 4.3x |
| Tue, 31 Jan 2023 | JP¥938.2b | JP¥186.7b | -JP¥24,854,541,000.00 | 39.1x | -37.7x | 5x |
| Thu, 29 Dec 2022 | JP¥887.6b | JP¥186.8b | -JP¥24,722,604,000.00 | 40.1x | -35.9x | 4.8x |
| Sat, 26 Nov 2022 | JP¥906.3b | JP¥182.1b | -JP¥23,614,604,000.00 | 45.9x | -38.4x | 5x |
| Mon, 24 Oct 2022 | JP¥836.1b | JP¥176.5b | -JP¥24,974,270,000.00 | 46.4x | -33.5x | 4.7x |
| Wed, 21 Sep 2022 | JP¥876.9b | JP¥176.5b | -JP¥24,974,270,000.00 | 45.5x | -35.1x | 5x |
| Fri, 19 Aug 2022 | JP¥967.0b | JP¥174.4b | -JP¥21,144,270,000.00 | 22.1x | -45.7x | 5.5x |
| Sun, 17 Jul 2022 | JP¥944.8b | JP¥171.3b | -JP¥16,112,943,000.00 | 21.3x | -58.6x | 5.5x |
| Tue, 14 Jun 2022 | JP¥864.6b | JP¥171.2b | -JP¥17,280,721,000.00 | 21.8x | -50x | 5.1x |
| Thu, 12 May 2022 | JP¥984.2b | JP¥164.6b | -JP¥13,891,328,000.00 | 14.1x | -70.9x | 6x |
| Sat, 09 Apr 2022 | JP¥1.1t | JP¥164.2b | -JP¥13,043,295,000.00 | 15.4x | -83.8x | 6.7x |
| Mon, 07 Mar 2022 | JP¥1.1t | JP¥159.9b | -JP¥9,023,798,000.00 | 14.9x | -117.8x | 6.6x |
| Wed, 02 Feb 2022 | JP¥1.0t | JP¥163.7b | -JP¥5,382,824,000.00 | 15.9x | -190.7x | 6.3x |
| Fri, 31 Dec 2021 | JP¥1.2t | JP¥163.5b | -JP¥5,447,524,000.00 | 18.4x | -226x | 7.5x |
| Sun, 28 Nov 2021 | JP¥1.3t | JP¥159.5b | -JP¥8,763,358,000.00 | 18.9x | -146.1x | 8x |
Price to Earnings Ratio
-146.1x
Current Industry PE
- Investors are relatively neutral on the Japanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 9.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Japanese Healthcare industry?
| JP Market | -0.44% | |
| Healthcare | -3.15% | |
| Biotech | -5.46% | |
| Biotech | -5.46% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 7776 CellSeed | JP¥563.00 | 19.0% +JP¥3.1b | 81.0% | n/a | |
| 4576 D. Western Therapeutics Institute | JP¥102.00 | 47.8% +JP¥1.3b | -37.8% | PS8.3x | |
| 4883 Modalis Therapeutics | JP¥134.00 | 19.6% +JP¥1.2b | 3.9% | PB3x | |
| 4978 ReproCELL | JP¥116.00 | 11.5% +JP¥1.1b | -45.5% | PS4.2x | |
| 219A Heartseed | JP¥1.34k | 2.6% +JP¥747.9m | n/a | n/a |
